Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Call Transcripts

Amylyx Pharmaceuticals, Inc.'s Latest Earnings Call - June 10, 2026

In the Q2 2026 earnings call for Amylyx Pharmaceuticals, the focus was on the upcoming Phase III results for Avexitide, a treatment for post-bariatric hypoglycemia (PBH). Management confirmed that the last participant was enrolled in March, with top-line results expected in Q3 2026. The company has cash runway into 2028, supporting plans for commercialization in 2027. Revenue and earnings figures were not disclosed, but management's confidence in the product's potential and the growing patient population could positively influence stock performance.

Reported metrics

Guidance from management

Management is preparing for commercialization of Avexitide in 2027 and has cash runway into 2028, indicating confidence in their operational strategy and financial health.

What management said

Well, so we're saying Q3, but to your point, to say what we've said. So we enrolled the last participant in the study at the end of March. So it's a 16-week double-blind placebo-controlled trial. So -- and then a little time for cleaning database lock and analysis. So that puts us nicely in Q3, and we're working hard leading up to those, that exciting milestone.

Yes. Well, I would say that, again, the most important thing is first try to enroll the right people in the study and have good site investigators that you're partnering with. But then it's about not only training but monitoring. What's nice in this study is that our team has access to the data in virtually real time because people are checking their fingerstick blood glucose, they're filling out their diaries. Every...

What analysts pressed on

Analysts expressed concerns regarding the delay in Phase III enrollment, questioning whether it reflects a lack of enthusiasm for the product. Management reassured that recruitment was efficient and that market research showed strong interest among physicians.

Main topics on the call

• Phase III Trial Progress — Management confirmed that the last participant in the Phase III trial of Avexitide was enrolled in March 2026, with top-line results anticipated in Q3 2026. They stated, "we're working hard leading up to those, that exci...
• Market Opportunity for PBH — The estimated patient population for PBH in the U.S. is around 160,000, with management noting that this population is expected to grow due to increasing bariatric surgeries. They emphasized that PBH is a severe conditio...
• Commercialization Strategy — Management is preparing for the launch of Avexitide in 2027, with a focus on partnering with high-volume endocrinology centers. They noted, "we think we're really going to want to make sure that we are partnering with th...
• Clinical Trial Design and Robustness — The Phase III trial design builds on previous successful trials, with management stating they are "90% powered to see a 35% relative difference" based on conservative assumptions. This highlights confidence in the trial'...

Read the full Amylyx Pharmaceuticals, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 37 Amylyx Pharmaceuticals, Inc. earnings call transcripts on record, spanning June 9, 2022 to August 6, 2026. Based on this history, Amylyx Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

AMLX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

37

First call

June 9, 2022

Most recent

August 6, 2026

Reporting cadence

quarterly